Last update June 13, 2022

N05BE01

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

Anxiolytic with little sedative action indicated in the treatment of anxiety disorders. Oral administration in two or three daily doses.

In one mother taking buspirone, milk levels were undetectable and plasma levels of buspirone were not detected in the infant. (Brent 1998)

No problems attributable to buspirone have been observed in two infants whose mothers were taking it. (Brent 1998, Newport 2009)

Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable, especially during the neonatal period and in the event of prematurity.

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

N05BE01 is Buspirone Hydrochloride in ATC Code/s.

Is written in other languages:

Group

N05BE01 belongs to this group or family:

Tradenames

Main tradenames from several countries containing N05BE01 in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 5 %
Molecular weight 422 daltons
Protein Binding 95 %
VD 5.3 l/Kg
pKa 7.6 -
Tmax 0.8 - 1.5 hours
T½ 2 - 4 hours
M/P ratio 0 -
Theoretical Dose 0 mg/Kg/d
Relative Dose 0 %

References

  1. Amir LH, Pirotta MV, Raval M. Breastfeeding--evidence based guidelines for the use of medicines. Aust Fam Physician. 2011 Sep;40(9):684-90. Review. Abstract Full text (link to original source) Full text (in our servers)
  2. Newport DJ, Ritchie JC, Knight BT, Glover BA, Zach EB, Stowe ZN. Venlafaxine in human breast milk and nursing infant plasma: determination of exposure. J Clin Psychiatry. 2009 Abstract
  3. Brent NB, Wisner KL. Fluoxetine and carbamazepine concentrations in a nursing mother/infant pair. Clin Pediatr (Phila). 1998 Abstract

Total visits

608

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM